Cue Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Net Income	-50.73	-53.01	-44.16	-44.78	-36.7	-38.98	-23.23	-7.66	-1.93
Depreciation & Amortization	3.44	1.81	1.26	1.06	0.81	0.76	0.42	0.2	0.04
Share-Based Compensation	8.18	9.5	11.52	10.48	6.52	7.17	2.78	0.89	0
Other Operating Activities	-0.84	-0.1	-7.45	0.75	-1.43	4.64	7.9	0.6	0.23
Operating Cash Flow	-39.96	-41.81	-38.84	-32.49	-30.8	-26.41	-12.14	-5.97	-1.66
Capital Expenditures	0	-0.17	-0.89	-0.6	0.08	-1.85	-1.03	-0.52	-0.75
Change in Investments	25	-24.45	10	5.05	3.37	-18.5	-0	-0	-0.05
Other Investing Activities	-	-	-	-	-	-	-0.18	-	-
Investing Cash Flow	25	-24.61	9.11	4.46	3.45	-20.35	-1.2	-0.52	-0.8
Share Issuance / Repurchase	13.86	44	19.98	58.89	50.79	4.18	66.16	16.41	10
Debt Issued / Paid	-2	9.86	0	0	0	0	0	0	0
Other Financing Activities	-	-0.2	-0.75	-0.27	-	-	-4.16	-1.41	-1.14
Financing Cash Flow	11.86	53.66	19.23	58.61	50.79	4.18	62	15.01	8.87
Net Cash Flow	-3.1	-12.76	-10.5	30.58	23.44	-42.58	48.66	8.52	6.41
Free Cash Flow	-39.96	-41.97	-39.73	-33.09	-30.72	-28.27	-13.17	-6.48	-2.41
Free Cash Flow Margin	-727.85%	-3371.16%	-265.90%	-1049.01%	-888.17%	-2473.75%	-	-	-
Free Cash Flow Per Share	-0.87	-1.18	-1.27	-1.15	-1.39	-1.40	-1.23	-0.87	-0.43

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).